Teva Pharmaceutical Industries ADR (TEVA) Stock Price, Quote & News

Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 972 3 914 8213

Website: www.tevapharm.com

Address:

124 Dvora HaNevi’a St., Tel Aviv-Yafo, Israel

LakersandVRX Feb. 3 at 8:17 PM

$TEVA All things work...until it stops working. ST speculators thought they understood TEVA...until their logic no longer works.

0 · Reply

RunnerSignals Feb. 3 at 6:32 PM

Fresh highs alert! $XOM $WMT $CSCO $KO $TEVA breaking out with momentum and volume

0 · Reply

InstitutionalDiscussion Feb. 3 at 5:03 PM

$TEVA $NVDA Pharma and technology mix

0 · Reply

d_risk Feb. 3 at 4:31 PM

$TEVA - Teva Pharmaceutical Industries Limited American Depositary Shares - 10K - Updated Risk Factors Teva’s 2026 10-K risk factors sharpen the picture of a generics-heavy business under mounting pressure: tougher global pricing and tenders, intense competition in generics/biosimilars and key brands, execution and IP risks around launches, expanded AI/cyber and data liability exposure, heavier geopolitical and supply-chain vulnerabilities, ongoing opioid and broader regulatory/litigation overhangs, and restructuring/divestiture moves (including planned API sale) that could disrupt its Pivot to Growth strategy. #Pharmaceuticals #AICybersecurity #SupplyChainVulnerability #RegulatoryRisk #GenericsCompetition 🟢 Added 🟠 Removed https://d-risk.ai/TEVA/10-K/2026-02-03

0 · Reply

SdotRayborn Feb. 3 at 4:05 PM

$TEVA GOING FOR THE JUGULAR

0 · Reply

DailyAnalysis Feb. 3 at 3:57 PM

$TEVA 1W breakout is verified. 1D RSI is hot, but 4H CCI confirms trend strength. Scaling in on 30M STOCH resets to ride the ongoing momentum toward the next key level. @DailyAnalysis

0 · Reply

Hshshhssos Feb. 3 at 3:44 PM

$TEVA you know the party is just getting started when TerraDumb is pretending to have been long this whole time

0 · Reply

tkstockpicker Feb. 3 at 3:41 PM

$TEVA nice

0 · Reply

DocDriz Feb. 3 at 3:40 PM

$TEVA This move and volume isn’t grandma Mabel adding to the Brookdale Senior Center investment club portfolio.

0 · Reply

1lanKa Feb. 3 at 3:36 PM

$TEVA Louise Chen Analyst, Scotiabank Q "Hi, congrats on the quarter, and thanks for taking my questions here. So, my first question was I wanted to ask you where you see the greatest disconnect between what you're excited about in your pipeline and what the Street is really missing on those products" Richard Francis: " Look, I'll never say anybody's missing anything because everybody is very experienced in this business. I do think that our pipeline has come along very fast and thick and fast. Maybe that's caught people unaware"

0 · Reply

Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript

Jan 28, 2026, 12:22 PM EST - 6 days ago

Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook

Jan 28, 2026, 7:31 AM EST - 6 days ago

Teva Pharmaceutical profit, revenue rise in fourth quarter

Jan 28, 2026, 7:00 AM EST - 6 days ago

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Jan 27, 2026, 8:00 AM EST - 7 days ago

Will Forte Teams Up with Teva to Get Real About Huntington's Disease with ‘Honestly HD'

Jan 14, 2026, 5:02 PM EST - 20 days ago

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Jan 14, 2026, 8:01 AM EST - 20 days ago

Teva Is No Longer A Turnaround Story, It's A Growth One

Jan 13, 2026, 2:46 PM EST - 21 days ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 12:26 PM EST - 22 days ago

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

RPRX

Jan 12, 2026, 10:46 AM EST - 22 days ago

Why Investors Are So Optimistic on Teva

Jan 11, 2026, 6:00 PM EST - 23 days ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Jan 11, 2026, 5:00 PM EST - 23 days ago

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Jan 5, 2026, 4:30 PM EST - 4 weeks ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 2, 2026, 8:58 AM EST - 4 weeks ago

Top 2 Health Care Stocks That May Crash In Q1

EXAS

Dec 24, 2025, 8:36 AM EST - 5 weeks ago

S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Dec 23, 2025, 6:08 PM EST - 6 weeks ago

Teva Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)

Dec 19, 2025, 3:40 AM EST - 6 weeks ago

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Dec 9, 2025, 8:00 AM EST - 2 months ago

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Dec 4, 2025, 2:08 PM EST - 2 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 25, 2025, 8:10 AM EST - 2 months ago

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Nov 21, 2025, 4:30 PM EST - 2 months ago

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December

Nov 19, 2025, 8:07 AM EST - 2 months ago

Teva seeks startups to help solve global pharmaceutical challenges

Nov 18, 2025, 8:58 AM EST - 2 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 14, 2025, 10:38 AM EST - 2 months ago

Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business

Nov 10, 2025, 2:51 PM EST - 3 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 6:00 PM EST - 3 months ago

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Nov 5, 2025, 1:02 PM EST - 3 months ago

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Nov 5, 2025, 1:01 PM EST - 3 months ago

Teva Pharmaceutical Industries Limited (TEVA) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 11:30 AM EST - 3 months ago

Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook

Nov 5, 2025, 9:14 AM EST - 3 months ago

Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Nov 5, 2025, 7:44 AM EST - 3 months ago

Teva Pharm third-quarter profit tops estimates as branded drugs gain

Nov 5, 2025, 7:00 AM EST - 3 months ago

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

Oct 31, 2025, 4:30 PM EDT - 3 months ago

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

Oct 30, 2025, 11:45 AM EDT - 3 months ago

Blood pressure medicine recalled over high levels of cancer-causing chemical

Oct 20, 2025, 4:30 PM EDT - 3 months ago

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Oct 17, 2025, 12:18 PM EDT - 3 months ago

Teva Vs. Viatris: Who Will Dominate In President Trump's America?

VTRS

Oct 10, 2025, 3:00 PM EDT - 4 months ago

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Oct 7, 2025, 4:07 AM EDT - 4 months ago

Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside

Sep 25, 2025, 4:30 PM EDT - 4 months ago

Teva Releases Q3 2025 Aide Memoire

Sep 25, 2025, 4:30 PM EDT - 4 months ago

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Sep 25, 2025, 11:42 AM EDT - 4 months ago

Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors

Sep 24, 2025, 7:23 AM EDT - 4 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 22, 2025, 2:53 PM EDT - 4 months ago

Teva Pharmaceutical Industries Limited - Special Call

Sep 20, 2025, 10:15 PM EDT - 4 months ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Sep 17, 2025, 8:00 AM EDT - 4 months ago

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

Sep 16, 2025, 4:30 PM EDT - 5 months ago

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Sep 9, 2025, 12:57 PM EDT - 5 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 5, 2025, 3:57 PM EDT - 5 months ago

Colorado must face Teva's lawsuit over free allergy pen law

Sep 2, 2025, 4:30 PM EDT - 5 months ago

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Aug 28, 2025, 9:17 AM EDT - 5 months ago

US FDA approves Teva Pharmaceuticals' generic obesity drug

LakersandVRX Feb. 3 at 8:17 PM

$TEVA All things work...until it stops working. ST speculators thought they understood TEVA...until their logic no longer works.

0 · Reply

RunnerSignals Feb. 3 at 6:32 PM

Fresh highs alert! $XOM $WMT $CSCO $KO $TEVA breaking out with momentum and volume

0 · Reply

InstitutionalDiscussion Feb. 3 at 5:03 PM

$TEVA $NVDA Pharma and technology mix

0 · Reply

d_risk Feb. 3 at 4:31 PM

0 · Reply

SdotRayborn Feb. 3 at 4:05 PM

$TEVA GOING FOR THE JUGULAR

0 · Reply

DailyAnalysis Feb. 3 at 3:57 PM

$TEVA 1W breakout is verified. 1D RSI is hot, but 4H CCI confirms trend strength. Scaling in on 30M STOCH resets to ride the ongoing momentum toward the next key level. @DailyAnalysis

0 · Reply

Hshshhssos Feb. 3 at 3:44 PM

$TEVA you know the party is just getting started when TerraDumb is pretending to have been long this whole time

0 · Reply

tkstockpicker Feb. 3 at 3:41 PM

$TEVA nice

0 · Reply

DocDriz Feb. 3 at 3:40 PM

$TEVA This move and volume isn’t grandma Mabel adding to the Brookdale Senior Center investment club portfolio.

0 · Reply

1lanKa Feb. 3 at 3:36 PM

0 · Reply

SdotRayborn Feb. 3 at 3:31 PM

$TEVA that volume

1 · Reply

SdotRayborn Feb. 3 at 3:28 PM

$TEVA no fintwit bullshit no Reddit bullshit just steady gains 👍🏻

0 · Reply

DocDriz Feb. 3 at 3:12 PM

$TEVA TEVA - Outside of college, the most fun you can have with your pants still on.

0 · Reply

Turbofueled Feb. 3 at 2:01 PM

$LEXX All Eyes on $LEXX 🌋🌋🌋🌋🌋🌋🌋🌋🚀🚀🚀🚀🚀🚀🚀 Getting ready to explode!!! $NVO $TEVA $LLY $MRK

0 · Reply

Quantumup Feb. 3 at 1:26 PM

H.C. Wainwright reiterated $AQST Buy/$10 $SPRY $NSRX $TEVA $VTRS Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2018676414778630511?s=20

0 · Reply

layahoo Feb. 3 at 3:54 AM

$TEVA It’s racing to $40.

1 · Reply

Makingmillions192 Feb. 3 at 2:57 AM

$TEVA Going to buy out $LEXX

0 · Reply

StockConsultant Feb. 3 at 2:41 AM

$TEVA TevaPharmaceutical stock good breakout follow through

0 · Reply

SdotRayborn Feb. 3 at 2:28 AM

$TEVA reminds me of HOOD move. Let’s see

0 · Reply

SdotRayborn Feb. 3 at 2:07 AM

$TEVA hope everyone’s ready for the expansion phase of the movement I’m thinking it may get violent here. 🧑🏻‍✈️

0 · Reply

TechridyStocks Feb. 3 at 1:59 AM

$MSGE $LTH $TEVA $VOD climbing daily shhhhhh @howardlindzon

0 · Reply

TechridyStocks Feb. 3 at 1:57 AM

$TEVA headed back to $50 easy

1 · Reply

Market Cap	39.09B
Revenue (ttm)	16.54B
Net Income (ttm)	-1.64B
EPS (ttm)	N/A
PE Ratio	11.77
Forward PE	12.51
Profit Margin	-9.91%
Debt to Equity Ratio	2.31

Volume	22,299,800
Avg Vol	10,446,136
Day's Range	N/A - N/A
Shares Out	1.15B
Stochastic %K	83%
Beta	0.66
Analysts	Strong Sell
Price Target	$35.73